BACKGROUND: Tumor markers have been extensively studied in lung cancer, reporting some relationship to the histology, but their clinical utility is not clear. METHODS: ProGRP, CEA, SCC, CA 125, CYFRA 21-1 and NSE were studied prospectively in 155 patients with unconfirmed suspicion of lung cancer and in 647 patients with lung cancer: 182 squamous, 205 adenocarcinomas, 19 large-cell lung cancer (LCLC), 175 small-cell lung cancer (SCLC) and 66 unspecific non-small-cell lung cancer (NSCLC). RESULTS: Abnormal tumor marker serum levels were found in less than 5.3% of the patients with benign diseases, excluding CA 125 (21.3%). Tumor markers were related to histological type and tumor extension with significantly higher CEA (p <0.01) and CA 125 (p <0.007) serum levels in adenocarcinomas, SCC (p <0.0001) and CYFRA 21-1 (p <0.008) in squamous tumors and ProGRP (p <0.0001) and NSE (p <0.0001) in SCLC. Tumor markers may be useful in the histological differentiation of NSCLC and SCLC. Patients with SCC serum levels >2 ng/ml were always NSCLC, while those with SCC <2 ng/ml and ProGRP >100 pg/ml and NSE >35 ng/ml were all SCLC patients. The sensitivity was 76.7 and 79.5%, specificity was 97.2 and 99.6%, with a positive predictive value of 98.6 and 98.6% and a negative predictive value of 60.7 and 92.9% in the differentiation of NSCLC and SCLC, respectively. CONCLUSIONS: Tumor marker determination in patients with suspicious signs of lung cancer suggests, in a few hours, the histological diagnosis in the majority of lung cancer patients. Copyright 2009 S. Karger AG, Basel.
BACKGROUND:Tumor markers have been extensively studied in lung cancer, reporting some relationship to the histology, but their clinical utility is not clear. METHODS:ProGRP, CEA, SCC, CA 125, CYFRA 21-1 and NSE were studied prospectively in 155 patients with unconfirmed suspicion of lung cancer and in 647 patients with lung cancer: 182 squamous, 205 adenocarcinomas, 19 large-cell lung cancer (LCLC), 175 small-cell lung cancer (SCLC) and 66 unspecific non-small-cell lung cancer (NSCLC). RESULTS:Abnormal tumor marker serum levels were found in less than 5.3% of the patients with benign diseases, excluding CA 125 (21.3%). Tumor markers were related to histological type and tumor extension with significantly higher CEA (p <0.01) and CA 125 (p <0.007) serum levels in adenocarcinomas, SCC (p <0.0001) and CYFRA 21-1 (p <0.008) in squamous tumors and ProGRP (p <0.0001) and NSE (p <0.0001) in SCLC. Tumor markers may be useful in the histological differentiation of NSCLC and SCLC. Patients with SCC serum levels >2 ng/ml were always NSCLC, while those with SCC <2 ng/ml and ProGRP >100 pg/ml and NSE >35 ng/ml were all SCLCpatients. The sensitivity was 76.7 and 79.5%, specificity was 97.2 and 99.6%, with a positive predictive value of 98.6 and 98.6% and a negative predictive value of 60.7 and 92.9% in the differentiation of NSCLC and SCLC, respectively. CONCLUSIONS:Tumor marker determination in patients with suspicious signs of lung cancer suggests, in a few hours, the histological diagnosis in the majority of lung cancerpatients. Copyright 2009 S. Karger AG, Basel.
Authors: Rafael Molina; Xavier Bosch; Josep M Auge; Xavier Filella; José M Escudero; Víctor Molina; Manel Solé; Alfonso López-Soto Journal: Tumour Biol Date: 2011-12-09
Authors: Rafael Molina; Jose M Escudero; Jose M Augé; Xavier Filella; Laura Foj; Aureli Torné; Jose Lejarcegui; Jaume Pahisa Journal: Tumour Biol Date: 2011-08-24
Authors: M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren Journal: Eur J Neurol Date: 2010-09-29 Impact factor: 6.089
Authors: Charles M Rudin; Ann Mauer; Martin Smakal; Rosalyn Juergens; Stanislav Spelda; Michael Wertheim; Andrew Coates; Evelyn McKeegan; Peter Ansell; Xiangdong Zhou; Jane Qian; Rajendra Pradhan; Barry Dowell; Andrew Krivoshik; Gary Gordon Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 44.544
Authors: Charles M Rudin; Christine L Hann; Edward B Garon; Moacyr Ribeiro de Oliveira; Philip D Bonomi; D Ross Camidge; Quincy Chu; Giuseppe Giaccone; Divis Khaira; Suresh S Ramalingam; Malcolm R Ranson; Caroline Dive; Evelyn M McKeegan; Brenda J Chyla; Barry L Dowell; Arunava Chakravartty; Cathy E Nolan; Niki Rudersdorf; Todd A Busman; Mack H Mabry; Andrew P Krivoshik; Rod A Humerickhouse; Geoffrey I Shapiro; Leena Gandhi Journal: Clin Cancer Res Date: 2012-04-11 Impact factor: 12.531